Status:
RECRUITING
RWE of 1st Line Treatment With ATO/ATRA for Adult APL
Lead Sponsor:
Grupo Argentino de Tratamiento de la Leucemia Aguda
Conditions:
Promyelocytic Leukemia, Adult Acute
Eligibility:
All Genders
18+ years
Brief Summary
This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of acute promyelocytic leukemia (APL) patients in the first line with...
Detailed Description
The purpose of this trial is to gather real world evidence of the characteristics of APL patients in Argentina who receive ATO/ATRA based treatment in first line following our national guidelines. The...
Eligibility Criteria
Inclusion
- Patients 18 years or older.
- Signature of the form consent for participation in the study.
- Diagnosis of APL (either primary or secondary) according to the criteria of the World Health Organization (WHO), without prior treatment.
- Identification of the specific genetic alteration of APL by conventional karyotype, fluorescent in situ hybridization (FISH), reverse transcriptase polymerase chain reaction (RT-PCR or RQ-PCR). Identification of the transcript is recommended at the time of diagnosis isoforms: bcr1, bcr2, bcr3 essential to document the therapeutic response: Molecular remission
Exclusion
- Presence of other concomitant active malignant tumors that require simultaneous treatment.
- Having received prior treatment for APL.
- Electrocardiogram abnormalities:
- Patients with a pre-existing diagnosis of Long QT Syndrome
- Patients with a baseline QTc of\> 450msec. The Bazett formula should be used to measure the corrected QT interval (QT interval in msec divided by the square root of the RR interval in msec).
- Patients with a history or presence of significant ventricular or atrial tachyarrhythmia (Grade 3-4, CTCAE v5.2017).
- Patients with right bundle branch block plus left anterior hemiblock. Bifascicular blocks are excluded.
- ECOG score 4.
- Stage III-IV heart failure.
- Serum creatinine ≥ 2.5 mg / dL (≥ 250 μmol / L) unless due to APL.
- Bilirubin ≥ 2.5 mg / dL, alkaline phosphatase, GPT or GOT\> 3 times the normal limit unless it is for APL.
- Severe psychiatric illness.
- Women who are pregnant or who have decided to continue breastfeeding.
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04897490
Start Date
March 1 2021
End Date
December 1 2026
Last Update
January 9 2024
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Italiano de La Plata
La Plata, Buenos Aires, Argentina
2
Instituto Privado de Hematologia y Hemoterapia
Paraná, Entre Ríos Province, Argentina
3
Hospital Escuela de Agudos Dr. Ramón Madariaga
Posadas, Misiones Province, Argentina
4
Hospital Descentralizado Dr. Guillermo Rawson
Rawson, San Juan Province, Argentina